Gilead Sciences Inc. (GILD): Management meeting frames strategy across pipeline portfolio

Research evidence excerpt

Gilead Sciences Inc. (GILD): Management meeting frames strategy across pipeline portfolio

ct 1989) in New Zealand. This research, and any access to it, is intended for

“wholesale clients” (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs

Australia and New Zealand disclosure of interests is available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html.

Russia: Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis

not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity.

Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a

specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no

responsibility for any investment decisions that may be taken by a client or any other person based on this research report. Singapore: Goldman Sachs

(Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this

research, and should be contacted with respect to any matters arising from, or in connection with, this research. Taiwan: This material is for reference

only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the

responsibility of the individual investor. United Kingdom: Persons who would be categorized as retail clients in the United Kingdom, as such term is